Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
AdCompositivemRNA-1010Positive
AI Analysis
Summary
Moderna announced that the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously (9-0) in favor of the benefit-risk profile of mRNA-1010, its investigational seasonal influenza vaccine candidate.
Outcome Details
VRBPAC voted 9-0 in favor of the benefit-risk profile of mRNA-1010
Importance:8/10
Sentiment:
0.85
FDA Advisory CommitteevaccineinfluenzaVRBPACunanimous vote
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on June 18, 2026 11:08 PM